Skip to main content
OpenTrials
Completed

NCT Number: NCT02205827

A Study to Determine the Inter/Intra Observer and Intra-subject Variability of Whole Blood Clotting Time Measurements

The purpose of the study is to characterize the distribution and sources of variability in whole blood clotting time (WBCT) measurements in human blood collected from healthy volunteers by 5 different technicians.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Quintiles Phase I Services, LLC

Overland Park, Kansas, 66211, United States

About this study

No investigational product was administered to any subject in this study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed and dated, written informed consent (Institutional Review Board [IRB]-approved informed consent form [ICF]).
  • Healthy male and female subjects aged 18 to 65 years (inclusive) with suitable veins for venipuncture. (Healthy as determined by medical history)

Exclusion criteria

  • Healthy subjects who do not conform to the above inclusion criteria.
  • Healthy subjects who cannot communicate reliably with the Investigator.
  • History of major bleeding or major trauma within the past 6 months
  • Healthy volunteer with a propensity to bleed (i.e. due to recent trauma, recent surgery, peptic ulcer, active or recent gastrointestinal bleeding or bleeding from hemorrhoids).
  • Significant infection or known inflammatory process within 2 weeks of screening.
  • Treatment with any investigational products or therapies within 30 days (or 5 half lives, whichever is greater) prior to screening.
  • Received non-steroidal anti-inflammatory (NSAID) or medications (including any type of anticoagulant or aspirin [ASA]) with a direct effect on hemostasis within 7 days of testing
  • Unwillingness or inability to comply with procedures required in this protocol.
  • Subjects who are concurrently enrolled in any other clinical study.

Treatment and study plan

Single-arm

Other

collection of blood for assessment of whole blood clotting time

Other names: Whole Blood Clotting Time assessment

Primary outcomes

  1. Variability in whole blood clotting time measurement

    Time frame: 1 day

    Assessment of variability in whole blood clotting time measurements in human blood collected from volunteers in across five technicians

Sponsors and collaborators

Lead sponsor

Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.

Industry

Collaborators

  • Quintiles, Inc.

Registry information

Important dates

Study start
2014
Primary completion
2014
Study completion
2014
First posted
Jul 31, 2014
Registry last updated
May 20, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.